Integrated Filing — IndAS



General information about company

Scrip Code 524372
NSE Symbol ORCHPHARMA
MSEI Symbol NOTLISTED
ISIN INE191A01027
Name of company Orchid Pharma Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 11-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 06-02-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Third quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 11-02-2026   13:30:00
End date and time of board meeting 11-02-2026   17:15:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 20,726.70 57,372.00
Other income 560.94 2,783.14
Total income 21,287.64 60,155.14
2 Expenses
(a) Cost of materials consumed 11,896.58 34,139.09
(b) Purchases of stock-in-trade 25.00 121.13
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 2,393.08 3,191.63
(d) Employee benefit expense 2,412.75 7,059.10
(e) Finance costs 317.77 1,016.75
(f) Depreciation, depletion and amortisation expense 902.94 2,658.49
(f) Other Expenses
1 Other Expenses 3,842.89 11,434.69
Total other expenses 3,842.89 11,434.69
Total expenses 21,791.01 59,620.88
3 Total profit before exceptional items and tax (503.37) 534.26
4 Exceptional items (711.27) (711.27)
5 Total profit before tax (1,214.64) (177.01)
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax 0.00 (19.33)
9 Total tax expenses 0.00 (19.33)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (1,214.64) (157.68)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method (46.71) (165.64)
16 Total profit (loss) for period (1,261.35) (323.32)
17 Other comprehensive income net of taxes 56.42 1.49
18 Total Comprehensive Income for the period (1,204.93) (321.83)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 5,071.91 5,071.91
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -2.49 -0.64
Diluted earnings (loss) per share from continuing operations -2.49 -0.64
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -2.49 -0.64
Diluted earnings (loss) per share from continuing and discontinued operations -2.49 -0.64
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above results for the quarter and nine months period ended December 31, 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on February 11 , 2026. The statutory auditors of the company have expressed a modified conclusion on the Limited review. 2. The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards rind AS) as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally acceptej in India, to the extent applicable. 3. The Government of India has consolidated the multiple existing labour legislations into a unified framework comprising of Labour Godes collectively referred to as New 'Labour Codes' which become effective from 21 Novemeber 2025. The company has reassessed the employee benefits obligations in accordance with the revised definition of wages. Accordingly, based on management assessment and actuarial valuation, an incrimentalliability on account of past service cost in accordance with IND AS19 'Employee Benefits' amounting to Rs. 711.271akhs has been shown under exceptional items in the Statement of Profit and Loss for the quarter and nine months ended December 31 , 2025 . Further in view of the relevant Rules yet to be notified, the company would continue to monitor developments relating to the implimentation of the New Labour Codes and will review its estimates and assumptions on an ongoing basis. 4. 99,02,705 fully paid up Equity Shares of face value Rs.10/- each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement (QIP) whereby proceeds of Rs.39180 Lakhs (Net of Share issue expenses) was raised. As on December 31 ,2025 the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below :Statement of QIP Net Funds raised and utilisation is furnished below: Statement of QIP Net Funds raised and utilisation Particulars Amount as stated in Total amount utilised Balance amount as on Remarks the Offer Document upto December 31, 2025 on December 31, 2025 kept (Rs. In Lakhs), (revised) (Rs. in Lakhs) in Fixed Deposits (Rs.in lakhs) 1. Investment in OBPL, subsidiary, for setting up Jammu Manufacturing Facility 13500 7302 6198 2. Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the company 19546 19546 - 3. Funding capital expenditure requirements for setting up a new block at the API facility of the Company in Alathur, Tamil Nadu 36 36 0 4. General corporate purposes 6372 6372 0 Total 39454 33256 6198 #As per the QIP offer document the amount allocated for General Corporate Purpose (GCP) was Rs.6098 Lakhs which was baseo on the proposed net proceeds after issue expenses being Rs.39180 Lakhs. However, net proceeds transferred to Monitoring Account was Rs.39454 Lakhs as against the proposed Net Proceeds of Rs.39180 Lakhs, therefore the surplus amount of Rs.274 Lakhs has been included in the GCP amount allocatedl utilized as on 31st December, 2025 . The Allocation among the objects has been revised vide Shareholde's resolution dated September 20, 2025. Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits. 5. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108 Operating Segments and hence no reporting as per Ind AS 108 is applicable. 6. The Company has submitted a petition with the Hon'ble National Company law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratones Limited (the Amalgamating Company) with the Company in compliance with Section 230-232 and other relevant provisions of the Companies Act 2013. The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation letter from the BSE Limited and National Stock Exchange of India Limited (stock exchanges) giving No objection to the said amalgamation. The requisite approvals of the concerned shareholders and creditors, as directed by the Hon'ble NClT have been duly secured. Further, the Companies submitted the Joint Company Petition seeking approval on the Scheme of Amalgamation. During the hearing held on February 04, 2026, Office of OfIicial Liquidator and Regional Director confinmed the submission of their respective reports. Pursuant thereto, the Hon'ble NCLT directed verification and adjoumed to the next hearing scheduled for March 02, 2026. 7. Figures of the previous period have been regrouped/reclassified/restated wherever considered necessary.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-12-2025 31-12-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be recalssified to profit and loss 56.42 1.49
Total Amount of items that will not be reclassified to profit and loss 56.42 1.49
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 56.42 1.49